EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome
NCT00056199
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
5
Enrollment
NIH
Sponsor class
Conditions
Hippel-Lindau Disease
Interventions
DRUG:
EYE001
Sponsor
National Eye Institute (NEI)